Unknown PHASE1 INTERVENTIONAL 10-arm NCT05650385

A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

A Multicenter, Open-label, Dose-escalating Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

Sponsor: Tasly Biopharmaceuticals Co., Ltd.

Conditions Neoplasms Malignant

Interventions B1962

Updated 4 times since 2023 Last updated: Dec 13, 2022 Started: Dec 31, 2022 Primary completion: Dec 31, 2023 Completion: Oct 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05650385, this PHASE1 trial focuses on Neoplasms Malignant and remains ongoing. Sponsored by Tasly Biopharmaceuticals Co., Ltd., it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Unknown PHASE1

Status: Not Yet Recruiting → Unknown
Sep 2024 — Dec 2025 [monthly]

Not Yet Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1
Jan 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tasly Biopharmaceuticals Co., Ltd.

Data source: Tasly Biopharmaceuticals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China